Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b first-in-human study of ASP1948 alone and with PD-1 inhibitors in advanced solid tumors
jRCT2031200341Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of ASP1948 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (mCRPC) and 5 more (3 arms), sponsored by Astellas Pharma. Primary endpoints: Safety and tolerability assessed by dose limiting toxicities (DLTs), Safety and tolerability assessed by Adverse Events (AEs) and 9 more. Started Feb 2021; status: completed.
02
Drugs
ASP1948
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)metastatic castration-resistant prostate cancer (mCRPC)ovarian cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2031200341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200341.